Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
Vincent FradetPaul TorenMolière Nguile-MakaoMichele LoddeJérome LévesqueCaroline LégerAndré CaronAlain BergeronTal Ben-ZviLouis LacombeFrédéric PouliotRabi TiguertThierry DujardinYves FradetPublished in: BJU international (2017)
The urinary PCA3 test predicted Gleason grade re-classification amongst patients receiving a 5ARI during AS for low-risk prostate cancer.